13F Holdings
中文EN

SNOA Sonoma Pharmaceuticals, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1367083 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY38.7%
TTM net income YoY48.4%
TTM EPS YoY55.2%
Revenue 3-yr CAGR24.7%
Net income 3-yr CAGR—

Margins

Gross margin39.2%
Operating margin-3.3%
Net margin-7.6%
FCF margin-11.9%
EBITDA margin-2.8%

Returns

ROE-34.5%
ROA-11.6%
ROIC (approx.)-44.6%
Asset turnover1.52x

Leverage & solvency

Liabilities / assets61.3%
Debt / equity0.00x
Current ratio3.48x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.49x
Accruals ratio5.6%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-31FY20252025-03-31FY20242024-03-31FY20232023-03-31FY20222022-03-31
Income statement
Revenue$19.53M$14.29M$12.73M$13.27M$12.63M
Cost of revenue$12.11M$8.82M$7.99M$8.79M$8.63M
Gross profit$7.42M$5.46M$4.75M$4.48M$3.99M
R&D expense$2.27M$1.81M$1.87M$207,000$125,000
SG&A expense$7.61M$7.36M$7.58M$8.84M$9.76M
Operating income-$2.46M-$3.71M-$4.70M-$4.57M-$5.89M
Pretax income-$3.42M-$2.91M-$5.03M-$5.18M-$5.42M
Income tax-$244,000$550,000-$196,000-$33,000-$332,000
Net income-$3.17M-$3.46M-$4.83M-$5.15M-$5.09M
EBITDA-$2.32M-$3.57M-$4.53M-$4.45M-$5.70M
EPS (basic)-1.89-2.79-10.63-1.52-1.92
EPS (diluted)-1.89-2.79-10.63-1.52-1.92
Weighted avg. shares (diluted)1.68M1.24M455,0003.39M2,653
Banking
Net interest income———$16,000-$10,000
Balance sheet
Cash & equivalents$2.40M$5.37M$3.13M$3.82M$7.40M
Receivables$2.53M$2.23M$2.90M$2.57M$2.41M
Inventory$3.65M$2.92M$2.72M$2.86M$2.66M
Current assets$12.10M$12.65M$12.55M$13.80M$16.43M
PP&E, net$310,000$225,000$365,000$488,000$320,000
Total assets$13.96M$13.69M$14.74M$16.23M$18.84M
Current liabilities$4.83M$4.10M$3.72M$3.72M$5.82M
Short-term debt$222,000$220,000$323,000$431,000—
Long-term debt————$0
Total debt————$0
Total liabilities$10.87M$9.28M$8.60M$8.25M$10.15M
Shareholders' equity$3.10M$4.41M$6.14M$7.98M$8.70M
Net debt————-$7.40M
Shares outstanding1.80M1.63M780,3714.93M3.10M
Cash flow statement
Operating cash flow-$3.93M-$88,000-$2.40M-$6.15M-$4.25M
Capital expenditure$192,000$80,000$2,000$269,000$137,000
Free cash flow-$4.12M-$168,000-$2.40M-$6.42M-$4.38M
Investing cash flow-$192,000-$80,000-$2,000-$258,000-$99,000
Financing cash flow$477,000$3.03M$1.68M$2.49M$7.40M
Depreciation & amortization$139,000$138,000$176,000$125,000$186,000
Stock-based compensation$255,000$224,000$516,000$669,000$382,000

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.